These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 29504948)

  • 41. The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy.
    Wei Y; Zhao Q; Gao Z; Lao XM; Lin WM; Chen DP; Mu M; Huang CX; Liu ZY; Li B; Zheng L; Kuang DM
    J Clin Invest; 2019 May; 129(8):3347-3360. PubMed ID: 31112529
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bispecific Antibody Expressed by an Oncolytic Herpes Simplex Virus Type 2 Can Transform Heterologous T Cells Into Uniform Tumor Killer Cells.
    Jin J; Wang R; Yang J; Hu H; Wang D; Cai L; Fang Z; Dong S; Hu S; Wang Y; Liu B
    Hum Gene Ther; 2022 Jun; 33(11-12):649-663. PubMed ID: 35272497
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Silencing PD-1 and PD-L1: the potential of PolyPurine Reverse Hoogsteen hairpins for the elimination of tumor cells.
    Ciudad CJ; Medina Enriquez MM; Félix AJ; Bener G; Noé V
    Immunotherapy; 2019 Apr; 11(5):369-372. PubMed ID: 30786843
    [No Abstract]   [Full Text] [Related]  

  • 44. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
    Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
    Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade.
    Najafi S; Majidpoor J; Mortezaee K
    Biomed Pharmacother; 2023 May; 161():114436. PubMed ID: 36841031
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers.
    Liberini V; Laudicella R; Capozza M; Huellner MW; Burger IA; Baldari S; Terreno E; Deandreis D
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33920423
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Current events in immunotherapy for upper aerodigestive tract cancer].
    Outh-Gauer S; Le Tourneau C; Broudin C; Scotte F; Roussel H; Hans S; Mandavit M; Tartour E; Badoual C
    Ann Pathol; 2017 Feb; 37(1):79-89. PubMed ID: 28111039
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Landscape of PD-1/PD-L1 Regulation and Targeted Immunotherapy.
    Ni JM; Ni AP
    Chin Med Sci J; 2018 Sep; 33(3):174-182. PubMed ID: 30266108
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.
    Ai L; Xu A; Xu J
    Adv Exp Med Biol; 2020; 1248():33-59. PubMed ID: 32185706
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.
    Huang A; Peng D; Guo H; Ben Y; Zuo X; Wu F; Yang X; Teng F; Li Z; Qian X; Qin FX
    Sci Rep; 2017 Feb; 7():42687. PubMed ID: 28202921
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
    Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
    Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response.
    Luo M; Fu L
    Oncotarget; 2016 May; 7(20):29794-803. PubMed ID: 26919108
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma.
    Liu CQ; Xu J; Zhou ZG; Jin LL; Yu XJ; Xiao G; Lin J; Zhuang SM; Zhang YJ; Zheng L
    Br J Cancer; 2018 Jul; 119(1):80-88. PubMed ID: 29921949
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Abscopal effects observed in cancer radiation therapy and oncolytic virotherapy: an overview.
    Romano G; Marino IR
    Drugs Today (Barc); 2019 Feb; 55(2):117-130. PubMed ID: 30816886
    [TBL] [Abstract][Full Text] [Related]  

  • 55. IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-β, Collagen Type I, and PD-L1/PD-1.
    Eriksson E; Milenova I; Wenthe J; Moreno R; Alemany R; Loskog A
    J Immunol; 2019 Feb; 202(3):787-798. PubMed ID: 30617223
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.
    Antonia SJ; Vansteenkiste JF; Moon E
    Am Soc Clin Oncol Educ Book; 2016; 35():e450-8. PubMed ID: 27249753
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade.
    Kowalsky SJ; Liu Z; Feist M; Berkey SE; Ma C; Ravindranathan R; Dai E; Roy EJ; Guo ZS; Bartlett DL
    Mol Ther; 2018 Oct; 26(10):2476-2486. PubMed ID: 30064894
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape.
    Noguchi T; Ward JP; Gubin MM; Arthur CD; Lee SH; Hundal J; Selby MJ; Graziano RF; Mardis ER; Korman AJ; Schreiber RD
    Cancer Immunol Res; 2017 Feb; 5(2):106-117. PubMed ID: 28073774
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.
    Hamanishi J; Mandai M; Matsumura N; Abiko K; Baba T; Konishi I
    Int J Clin Oncol; 2016 Jun; 21(3):462-73. PubMed ID: 26899259
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cancer immunotherapy using PolyPurine Reverse Hoogsteen hairpins targeting the PD-1/PD-L1 pathway in human tumor cells.
    Medina Enríquez MM; Félix AJ; Ciudad CJ; Noé V
    PLoS One; 2018; 13(11):e0206818. PubMed ID: 30399174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.